Liftstream is an executive search recruitment company in the life sciences sector
Northwest Biotherapeutics (NW Bio), a biotechnology company developing personalised immunotherapy products based in Bethesda, Maryland, has appointed Susan Bayh and Cofer Black as independent directors.
eFFECTOR Therapeutics, an early-stage company focused on the discovery and development of small molecule cancer therapeutics in San Diego, has secured its Series B financing up to USD 56 million. The new funding came from Sectoral Asset Management, a new investor in the syndicate, as well as existing investors. Meanwhile, eFFECTOR Therapeutics appointed Maha Katabi, a partner from Sectoral, to its board of directors.
PsiOxus Therapeutics, an immuno-oncology company in Oxford, England, has appointed Paolo Paoletti to Chairman of its Board to replace Michael Moore. Moore will remain on the Board as Deputy Chairman.
Scott Morrison, a retired Ernst & Young Partner, was appointed to the board of directors at Audentes Therapeutics and Global Blood Therapeutics.Watch Full Movie Online Streaming Online and Download
Idera Pharmaceuticals, a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, has appointed Maxine Gowen to its board of directors.
Rodin Therapeutics, a biotechnology company developing therapeutics for neurological disorders based in Cambridge, Mass, has appointed Samantha Singer as an independent member of the company’s board of directors. Singer is COO of the Broad Institute of MIT and Harvard, where she oversees the institute’s human resources, finance, facilities, and information technology teams, in addition to the Office of Strategic Alliances and Partnering.
Alnylam Pharmaceuticals, a biopharmaceutical company headquartered in Cambridge, Mass, has named Michael Bonney as Chairman to replace John Clarke who stepped down after 13 years of service. Clarke will remain on the board as a director of the company. Bonny is the current board member and former CEO of Cubist Pharmaceuticals.
Intellia Therapeutics, a genome editing company based in Cambridge, Massachusetts, has named Caroline Dorsa to its Board of Directors. Her appointment will help advance the company’s mission of developing therapeutics utilizing CRISPR/Cas9 gene-editing technology.Watch Full Movie Online Streaming Online and Download
Hans Schikan is former Chief Executive Officer of Prosensa, a biopharmaceutical company focusing on novel RNA modulating treatments for rare diseases like Duchenne muscular dystrophy. Prosensa was listed on NASDAQ (RNA) since June 2013. The company was acquired by BioMarin early 2015 for up to USD 840 million. Before joining Prosensa, Hans worked at Genzyme, including as Vice President for Global Marketing and Strategic Development of Genzyme’s product portfolio for rare genetic diseases. Prior to Genzyme, he worked at Organon, both at corporate level and in country operations which included assignments in Asia and Europe.
Wilson Therapeutics has announced that Andrew Kay has been appointed as Chairman of its Board of Directors. The company’s previous Chairman, Hugh Rienhoff, M.D. will continue to advise the company as a consultant.